AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction
AstraZeneca and Ionis face market volatility following the failure of their joint heart disease drug trial.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AstraZeneca and Ionis shares declined after the drug Wainua failed to meet its primary target in a heart disease clinical trial. The event marks a significant setback for the pharmaceutical companies involved.
Coverage from the Wall Street Journal, Reuters, CNBC, and Yahoo Finance highlights the downward movement in share prices. Analysts noted the slump for Ionis as the largest single-day decline in more than five years, while reports state AstraZeneca experienced a 9% drop in stock value.
Future reports will track the continued market performance of both companies. Coverage does not yet specify the long-term status of the Wainua program or subsequent regulatory filings.
Synthesized by PULSE from the headlines below under a strict no-invention contract. Updated 5h ago.
Quick answers
What caused the decline in share prices?
The decline followed news that the heart disease drug Wainua failed to meet its target in a clinical trial.
How did Ionis stock perform compared to previous years?
According to Yahoo Finance, the stock is heading toward its biggest single-day slump in over five years.
What is the status of the Wainua drug?
Coverage states the drug failed its key heart disease trial; reports do not specify next steps for the medication.
Coverage (5)
- AstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trial WSJ · 7h ago
- IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years Yahoo Finance · 7h ago
- AstraZeneca's Wainua fails key heart disease trial, shares tumble Reuters · 7h ago
- AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse CNBC · 7h ago
- AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction Fierce Pharma · 11h ago
Topics
Related trends
AstraZeneca, Ionis report major trial failure with heart disease drug
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Tobacco Stocks Are Coming in From the Cold
Tobacco sector equities see shifting market sentiment as firms pivot away from traditional cigarette production.
Stock Market Today: Nasdaq Futures Gain as Investors Take Mideast Tensions in Stride
Nasdaq futures trend upward despite global market volatility and renewed military engagement between the United States and Iran.
Stock futures inch higher as traders assess rising tensions between the U.S. and Iran: Live updates
Stock futures show mixed movement today as investors weigh shifting oil prices against escalating tensions between the U.S. and Iran.
Famed investor Jeremy Grantham says history will end up laughing at SpaceX, the 'craziest IPO in the history of man' that just joined the Nasdaq 100
SpaceX faces sharp scrutiny from investor Jeremy Grantham following its recent addition to the Nasdaq 100 index.
Stock futures are little changed as investors weigh Middle East tensions and await Fed minutes: Live updates
Global financial markets fluctuate as investors react to the collapse of the Iran ceasefire and anticipate upcoming Federal Reserve updates.